Axitinib clinical trials
Also written Inlyta and AG-013736.
How each study uses Axitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Axitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Jan 2012 · INLYTA · NDA 202324 (FDA, Drugs@FDA)
- European Union
- 3 Sept 2012 · Inlyta · EMEA/H/C/002406 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
139 studies that test it; most in 2011 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 6 |
| 2011 | 13 |
| 2012 | 12 |
| 2013 | 2 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 45 · Other 94
Pfizer (36) · Ocular Therapeutix, Inc. (5) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Memorial Sloan Kettering Cancer Center (3) · Chinese University of Hong Kong (3) · The Netherlands Cancer Institute (3)
Often tested with
Tested in the same studies.
Avelumab (13) · Pembrolizumab (11) · Nivolumab (6) · Toripalimab (6) · Crizotinib (6) · Palbociclib (5) · Sunitinib (5) · Erlotinib (5)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 1 in phase 3
Studies that test Axitinib, phase 3 first.
- Jan 2027Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationPhase 3 · Ocular Therapeutix, Inc.
- Nov 2026Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusPhase 2 · University of Colorado, Denver
- Nov 2026Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaPhase 1/2 · Fox Chase Cancer Center
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Jan 2027Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/ParagangliomaPhase 2 · Columbia University
- Feb 2027Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaPhase 2 · Peking Union Medical College Hospital
- May 2027Axitinib and Nivolumab for the Treatment of Mucosal MelanomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
- Oct 2027A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaPhase 2 · Stephanie Berg
Studies
Open first, then newest update. How each study uses Axitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 139
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Written as Axitinib
- MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasNot yet recruitingPhase 2Fudan UniversityNCT07816770Written as Axitinib
- TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07776717Written as Axitinib
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingPhase 2Stephanie BergNCT07123090Written as Axitinib
- SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell CarcinomaRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07744932Written as axitinib plus toripalimab
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationPhase 1Peking University Cancer Hospital & InstituteNCT06424626Written as AK104+Axitinib
- Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyRecruitingPhase 3Ocular Therapeutix, Inc.NCT07516132Written as OTX-TKI
- Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingPhase 2University of Colorado, DenverNCT05969496Written as Axitinib
- Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell CarcinomaNot yet recruitingNot applicableQilu Hospital of Shandong UniversityNCT07500831Written as Axitinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Axitinib
- Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05384496Written as axitinib
- Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCCRecruitingPhase 2Tianjin Medical University Second HospitalNCT07172386Written as Toripalimab and axitinib
- Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07159191Written as Envafolimab Injection, Axitinib Tablets
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Axitinib
- CARE1 Pragmatic Clinical TrialRecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT06364631Written as Axitinib
- Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT06211114Written as Axitinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Axitinib
- Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsRecruitingPhase 2Consorzio OncotechNCT05817903Written as Axitinib
- A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03595124Written as Axitinib
- Axitinib Before Surgery in Treating Patients With High-Risk Prostate CancerCompletedPhase 2City of Hope Medical CenterNCT01385059Written as axitinib
See all 139 studies that test Axitinib →
Given beside what is tested · 40 — Axitinib is usual care or a partner of the new treatment
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as Axitinib
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Axitinib
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingPhase 1/2PfizerNCT07227415Written as Axitinib
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441Written as Axitinib
- PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCCNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07630363Written as Axitinib
- Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell CarcinomaRecruitingPhase 3ZHOU FANGJIANNCT05738694Written as Axitinib plus Toripalimab
- An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingPhase 2Yonsei UniversityNCT07469683Written as SLC-3010 + Axitinib
- A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06962787Written as Axitinib
- SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCCRecruitingPhase 2Peking University First HospitalNCT06889649Written as Axitinib (VEGF-TKI)
- Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCRecruitingPhase 2Centre Leon BerardNCT05096390Written as Axitinib Oral Tablet [Inlyta]
- The Efficacy and Safety of KN046 Combined With AxitinibRecruitingPhase 2/3Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06020352Written as KN046 plus Axitinib
- Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05768464Written as Axitinib
- A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT04958473Written as Axitinib
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaCompletedPhase 2Hoffmann-La RocheNCT05805501Written as Axitinib
- Seleno-L Methionine (SLM)-Axitinib-PembrolizumabCompletedPhase 1/2Fernando Maciel BarbosaNCT05363631Written as Axitinib
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as Axitinib
- Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02912572Written as Axitinib
- A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaCompletedPhase 2AkesoNCT05256472Written as axitinib
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)CompletedPhase 1Merck Sharp & Dohme LLCNCT05017012Written as Axitinib
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedPhase 1PfizerNCT04458259Written as Axitinib
Showing 20 of 40.
As the comparator · 6 — what is tested is compared with Axitinib
- An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingPhase 2Yonsei UniversityNCT07469683Written as SLC-3010 + Axitinib
- Combination of Toripalimab and JS004 Therapy for ccRCCRecruitingPhase 2Fudan UniversityNCT06690697Written as Axitinib
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedPhase 2/3HutchmedNCT05522231Written as axitinib / everolimus
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaCompletedPhase 2Astellas Pharma Global Development, Inc.NCT02639182Written as Axitinib
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell CarcinomaTerminatedPhase 1/2Tracon Pharmaceuticals Inc.NCT01806064Written as TRC105 and Axitinib
- Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaStatus unknownPhase 2Peking University Cancer Hospital & InstituteNCT03941795Written as Axitinib 1 MG [Inlyta]
Codes
What other systems call Axitinib · ClinicalTrials.gg INT006807
- MeSH (NLM) D000077784AxitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) C9LVQ0YUXGAXITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1242999Confirmed FDA, Wikidata
- Wikidata Q4830631axitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38718AxitinibOne source FDA
- DrugBank DB06626One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077784 | Axitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | C9LVQ0YUXG | AXITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1242999 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4830631 | axitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38718 | Axitinib | One source FDA |
| DrugBank | DB06626 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.